Abingworth Bioventures 8 closes on $465m
Abingworth has held a final close for its new life sciences fund, Abingworth Bioventures 8 (ABV 8), on its $465m hard-cap, exceeding its $375m target.
More on Funds
Tikehau closes T2 Energy Transition Fund on €1.1bn
Fund targets European companies operating in the clean energy production, low-carbon transport and energy efficiency segments
Skylake Capital holds first close, makes first deal
Debut fund leads a $3m round in UK-based deep-learning startup Mindtrace
Afinum back on road for ninth fund
Predecessor vehicle, which raised €410m in 2017, is now 86% deployed
Advent Life Sciences raises $215m across two new funds
Funds invest in early- and mid-stage life sciences companies developing new therapeutics and technologies
Latest News
DBAG's Ding Gruppe bolts on Bergert Gruppe
Telecommunications service Ding Gruppe now has 1,000 employees and posts €200m in revenues
Nordian Capital sells BouWatch to Haniel
Mergermarket reported that the purchase price values the security systems business at €325m
Penta sells Mecom Group to US-based trade buyer
GP exits the meat-processing company 13 years after acquiring Mecom Humenne in 2008
Octopus-backed SimplyCook acquired by Nestlé
SimplyCook will continue to be led by its founding team from its base in London